| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | AIM ImmunoTech Inc.: AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast | 155 | GlobeNewswire (Europe) | OCALA, Fla., May 09, 2024to discuss the Company's Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET.
The call will be hosted by members of AIM's leadership team... ► Artikel lesen | |
| 06.05. | AIM ImmunoTech Inc.: AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® | 180 | GlobeNewswire (Europe) | OCALA, Fla., May 06, 2024® (rintatolimod), AIM's dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
AIM Chief Executive Officer... ► Artikel lesen | |
| 29.04. | AIM ImmunoTech Inc.: AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer | 227 | GlobeNewswire (Europe) | Next safety cohort to begin escalated dosing soonOCALA, Fla., April 29, 2024.
Investigators at Erasmus Medical Center ("Erasmus MC") in the Netherlands have completed the safety evaluation of patients... ► Artikel lesen | |
| 25.04. | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Release of the Next CEO Corner Segment | 1 | GlobeNewswire (USA) | ||
| 19.04. | AIM ImmunoTech Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 18.04. | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Release of the Next CEO Corner Segment | 1 | GlobeNewswire (USA) | ||
| 15.04. | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs | 914 | GlobeNewswire (Europe) | OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen... ► Artikel lesen | |
| 11.04. | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Release of the Next CEO Corner Segment | 2 | GlobeNewswire (USA) | ||
| 10.04. | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer | 139 | GlobeNewswire (Europe) | OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda... ► Artikel lesen | |
| 02.04. | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | 202 | GlobeNewswire (Europe) | Year marked by growing body of promising data demonstrating Ampligen's potential to address multiple high-value indications
Company to host conference call and webcast today, April 2nd at 8:30 AM... ► Artikel lesen | |
| 30.03. | AIM ImmunoTech Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 28.03. | AIM ImmunoTech Inc.: AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference | 1 | GlobeNewswire (USA) | ||
| 26.03. | AIM ImmunoTech Inc.: AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast | 227 | GlobeNewswire (Europe) | OCALA, Fla., March 26, 2024to discuss the Company's Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET.
The call will be hosted by members of AIM's leadership team... ► Artikel lesen | |
| 25.03. | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research | 229 | GlobeNewswire (Europe) | Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024," appears in the journal Clinical Cancer Research, one... ► Artikel lesen | |
| 20.03. | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Release of the Next CEO Corner Segment | 1 | GlobeNewswire (USA) | ||
| 15.03. | AIM ImmunoTech Inc.: AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity | 1 | GlobeNewswire (USA) | ||
| 07.03. | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Launch of CEO Corner Platform | 1 | GlobeNewswire (USA) | ||
| 29.02. | AIM ImmunoTech Inc.: AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update | 441 | GlobeNewswire (Europe) | Company continues progress across Ampligen® clinical development programs
Growing body of promising data demonstrates Ampligen's potential to address multiple high-value indications
OCALA, Fla.... ► Artikel lesen | |
| 20.02. | AIM ImmunoTech Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.02. | AIM ImmunoTech Inc.: AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer | 397 | GlobeNewswire (Europe) | Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 (NYSE American: AIM) ("AIM" or the "Company") today announced the first subject has been dosed at Erasmus... ► Artikel lesen |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 5.566 |
| EVOTEC | 4.924 |
| PLUG POWER | 4.845 |
| TUI | 4.800 |
| NEL | 3.717 |
| BAYER | 3.645 |
| AMC ENTERTAINMENT | 3.332 |
| RHEINMETALL | 2.568 |
| NORDEX | 1.621 |
| COMMERZBANK | 1.615 |
| ALIBABA | 1.609 |
| MERCEDES-BENZ | 1.521 |
| DELIVERY HERO | 1.452 |
| SIEMENS ENERGY | 1.445 |
| ALLIANZ | 1.402 |
| BYD | 1.374 |
| RWE | 1.359 |
| AIXTRON SE | 1.357 |
| NVIDIA | 1.339 |
| THYSSENKRUPP | 1.241 |
| DEUTSCHE BANK | 1.194 |
| VOLKSWAGEN | 1.082 |
| THYSSENKRUPP NUCERA | 1.031 |
| RENK GROUP | 1.010 |
| DEUTSCHE PFANDBRIEFBANK | 944 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
